[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 47 of about 47
1. Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O'Brien S: Mature T-cell leukemias. Cancer; 2005 Nov 1;104(9):1808-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature T-cell leukemias.
  • Mature T-cell and NK-cell leukemias are a group of relatively uncommon neoplasms derived from mature or postthymic T-cells accounting for a relatively small percentage of lymphoid malignancies.
  • The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of these disorders from their B-cell counterparts.
  • Herein, we review the clinical and pathological features of mature T-cell leukemias.
  • [MeSH-major] Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Human T-lymphotropic virus 1. Humans. Immunophenotyping. Leukemia, Lymphoid. Leukemia, Prolymphocytic / diagnosis. Leukemia, Prolymphocytic / drug therapy. Leukemia, Prolymphocytic / genetics. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. Middle Aged. Tumor Virus Infections

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16136598.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 143
  •  go-up   go-down


2. Naseem S, Gupta R, Kashyap R, Nityanand S: T-cell prolymphocytic leukemia: a report of two cases with review of literature. Indian J Hematol Blood Transfus; 2008 Dec;24(4):178-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: a report of two cases with review of literature.
  • T-cell Prolymphocytic Leukemia (T-PLL) is a mature post-thymic T-cell malignancy with aggressive clinical course.
  • The principal disease characteristics are organomegaly, skin lesions and raised lymphocyte counts.
  • T-PLL is a rare T-cell malignancy with characteristic clinical and laboratory features and a poor prognosis.
  • It needs to be differentiated from B-Cell prolymphocytic leukemia (B-PLL) and other mature T-cell lymphoproliferative disorders with predominant leukemic pattern.
  • Differentiation can be made by a comprehensive approach taking into account the clinical features, the cell morphology and the immunophenotype of leukemic cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Leukemia. 1990 Apr;4(4):262-6 [2366582.001]
  • [Cites] Blood. 1987 Oct;70(4):926-31 [3115337.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Br J Haematol. 1980 Jul;45(3):513-4 [6968583.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Surv Ophthalmol. 2004 Sep-Oct;49(5):525-36 [15325197.001]
  • [Cites] Lancet. 1973 Aug 4;2(7823):232-4 [4124423.001]
  • (PMID = 23100959.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3475431
  • [Keywords] NOTNLM ; Immunophenotyping / Prolymphocyte / T-PLL
  •  go-up   go-down


3. Cavalcanti Júnior GB, Sales VS, Cavalcanti e Silva DG, Lopes MC, Paiva Ade S, da Fonseca HE, do Nascimento Júniors FF, Fernandes MZ: Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia. Acta Cir Bras; 2005;20 Suppl 1:101-7
Genetic Alliance. consumer health - Leukemia, B-cell, chronic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia.
  • PURPOSE: CD5 is a T cell marker, aberrantly express in B cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL).
  • Other chronic B cell malignancies including hairy cell leukemia (HCL) and B cell prolymphocytic leukemia (B-PLL) are CD5 negative or express this antigen in a weak way.
  • In this study, CD5 expression was investigated in leukemic cells from 42 patients with chronic B cell lymphoproliferative disease.
  • METHODS: We studied the CD5 expression in leukemic cells from 42 patients with chronic B-cell malignancies by flow cytometry.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186976.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Cotta CV, Leventaki V, Atsaves V, Vidaki A, Schlette E, Jones D, Medeiros LJ, Rassidakis GZ: The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas. Cancer; 2008 Feb 1;112(3):552-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
  • Recent studies have shown that Id2 is overexpressed in some types of B-cell lymphoma, including classical Hodgkin lymphoma.
  • The authors of the current study hypothesized that Id2 also is overexpressed in T-cell lymphomas.
  • METHODS: By using reverse-transcriptase polymerase chain reaction (RT-PCR) and Western blot analyses, high Id2 messenger RNA (mRNA) and protein levels, respectively, were detected in all 4 T-cell anaplastic large cell lymphoma (ALCL) cell lines that were tested.
  • RESULTS: Immunohistochemistry results indicated that Id2 was expressed strongly in 21 of 27 (78%) ALCL tumors (79% anaplastic lymphoma kinase [ALK]-negative and 75% ALK-positive), in 5 of 10 (50%) extranodal natural killer/T (NK/T)-cell lymphomas of the nasal type, in 2 of 8 (25%) cutaneous ALCLs, in 2 of 9 (22%) enteropathy type T-cell lymphomas, in 1 of 5 (20%) peripheral T-cell lymphomas not otherwise specified, and in 1 of 8 (13%) T-cell prolymphocytic leukemias.
  • Other types of T-cell lymphoma were negative for Id2.
  • Because it is known that myc is expressed in ALCL, myc was inhibited selectively in 2 ALCL cell lines, resulting in a concentration-dependent decrease in Id2 mRNA and protein levels.
  • CONCLUSIONS: Taken together, the current data suggest that Id2 commonly is overexpressed in highly proliferative T-cell lymphomas, and its expression may result from transcriptional activation of myc in these tumors.
  • [MeSH-major] Inhibitor of Differentiation Protein 2 / metabolism. Lymphoma, T-Cell / metabolism. Proto-Oncogene Proteins c-myc / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Gene Expression Regulation, Neoplastic / physiology. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Humans. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology. Lymphomatoid Papulosis / metabolism. Lymphomatoid Papulosis / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Up-Regulation / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085637.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 2; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger
  •  go-up   go-down


5. Wang J, Hasui K, Utsunomiya A, Jia X, Matsuyama T, Murata F: Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL. J Clin Exp Hematop; 2008 Apr;48(1):1-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL.
  • Proliferation, apoptosis and p53 protein expression in adult T-cell leukemia (ATL) cells were investigated.
  • Twenty peripheral blood tissue specimens (PBTS) comprising 7 cases of acute type ATL, 7 cases of chronic type ATL and 6 other leukemias were examined by means of antigen retrieval and the polymer method employing anti-Ki67 antigen (MIB-1), anti-cleaved caspase-3, anti-single stranded DNA and three kinds of anti-p53 protein antibodies including DO7.
  • Most acute and chronic cases of ATL included more than 10% MIB-1-positive proliferating leukemia cells and more than 1% cleaved caspase-3-positive apoptotic cells.
  • Some cells which were positive for both MIB-1 and anti-cleaved caspase-3 antibody were observed in acute type ATL.
  • Nuclear deposition of p53 protein labeled by DO7 was often found in acute type (p < 0.05).
  • Within the medium-sized population of ATL cell nuclei, DO7-positive ATL cells had a smaller nuclear area factor (long axis x short axis) than DO7-negative ATL cells.
  • A few proliferating ATL cells entered apoptosis, and the appearance of a subclone of ATL cells with nuclear deposition of p53 protein labeled by DO7 characterized acute type.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434687.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


6. Mozos A, Royo C, Hartmann E, De Jong D, Baró C, Valera A, Fu K, Weisenburger DD, Delabie J, Chuang SS, Jaffe ES, Ruiz-Marcellan C, Dave S, Rimsza L, Braziel R, Gascoyne RD, Solé F, López-Guillermo A, Colomer D, Staudt LM, Rosenwald A, Ott G, Jares P, Campo E: SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica; 2009 Nov;94(11):1555-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.
  • BACKGROUND: Cyclin D1-negative mantle cell lymphoma is difficult to distinguish from other small B-cell lymphomas.
  • Overexpression of the transcription factor SOX11 has been observed in conventional mantle cell lymphoma.
  • The aim of this study was to determine whether this gene is expressed in cyclin D1-negative mantle cell lymphoma and whether its detection may be useful to identify these tumors.
  • DESIGN AND METHODS: The microarray database of 238 mature B-cell neoplasms was re-examined.
  • SOX11 protein expression was investigated immunohistochemically in 12 cases of cyclin D1-negative mantle cell lymphoma, 54 cases of conventional mantle cell lymphoma, and 209 additional lymphoid neoplasms.
  • RESULTS: SOX11 mRNA was highly expressed in conventional and cyclin D1-negative mantle cell lymphoma and in 33% of the cases of Burkitt's lymphoma but not in any other mature lymphoid neoplasm.
  • SOX11 nuclear protein was detected in 50 cases (93%) of conventional mantle cell lymphoma and also in the 12 cyclin D1-negative cases of mantle cell lymphoma, the six cases of lymphoblastic lymphomas, in two of eight cases of Burkitt's lymphoma, and in two of three T-prolymphocytic leukemias but was negative in the remaining lymphoid neoplasms.
  • Cyclin D2 and D3 mRNA levels were significantly higher in cyclin D1-negative mantle cell lymphoma than in conventional mantle cell lymphoma but the protein expression was not discriminative.
  • The clinico-pathological features and outcomes of the patients with cyclin D1-negative mantle cell lymphoma identified by SOX11 expression were similar to those of patients with conventional mantle cell lymphoma.
  • CONCLUSIONS: SOX11 mRNA and nuclear protein expression is a highly specific marker for both cyclin D1-positive and negative mantle cell lymphoma.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2006 Aug;56(8):440-8 [16872438.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1109-10 [16861358.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1216-22 [17296973.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):750-62 [17891190.001]
  • [Cites] Blood. 2008 Jan 15;111(2):800-5 [17934069.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1745-6 [18223179.001]
  • [Cites] Blood. 2007 Jan 1;109(1):271-80 [16960149.001]
  • [Cites] Haematologica. 2006 Jan;91(1):11-6 [16434365.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2253-61 [10733493.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):760-6 [14608904.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1051-6 [15252312.001]
  • [Cites] J Clin Pathol. 1989 Sep;42(9):962-72 [2794086.001]
  • [Cites] Am J Surg Pathol. 1991 Sep;15(9):819-28 [1951841.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):59-68 [9888704.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4365-74 [10361135.001]
  • [Cites] Haematologica. 2008 May;93(5):641-5 [18450732.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5683-90 [18391076.001]
  • [Cites] Histopathology. 2008 Jul;53(1):20-9 [18518902.001]
  • [Cites] Br J Haematol. 2008 Aug;142(4):538-50 [18564361.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Dec;47(12):1086-97 [18709664.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):248-52 [18729857.001]
  • [Cites] Haematologica. 2008 May;93(5):680-7 [18367489.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):516-26 [16098065.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4315-21 [16123218.001]
  • [CommentIn] Haematologica. 2009 Nov;94(11):1488-92 [19880776.001]
  • [ErratumIn] Haematologica. 2010 Sep;95(9):1620
  • (PMID = 19880778.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / 5U01CA114778-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SOX11 protein, human; 0 / SOXC Transcription Factors; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2770966
  •  go-up   go-down


7. Wanko SO, de Castro C: Hairy cell leukemia: an elusive but treatable disease. Oncologist; 2006 Jul-Aug;11(7):780-9
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hairy cell leukemia: an elusive but treatable disease.
  • Hairy cell leukemia (HCL) is a unique chronic lymphoproliferative disorder that can mimic or coexist with other clonal hematologic disorders and has been associated with autoimmune disorders.
  • It should be entertained as an alternative diagnosis in patients with cytopenias being assigned the diagnosis of aplastic anemia, hypoplastic myelodysplastic syndrome, atypical chronic lymphocytic leukemia, B-prolymphocytic leukemia, or idiopathic myelofibrosis.
  • The typical presentation is that of a middle-aged man with an incidental finding of pancytopenia, splenomegaly, and inaspirable bone marrow.
  • Relapsed disease after a prolonged remission can often be successfully retreated with the same initial agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / pathology. Leukemia, Hairy Cell / therapy

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880237.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; 9008-11-1 / Interferons
  •  go-up   go-down


8. Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff-Tavernier M, Ong J, Berger R, Leblond V, Merle-Béral H: Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genet Cytogenet; 2005 May;159(1):74-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin.
  • Burkitt-type acute leukemia cells were present in the bone marrow of a patient with B-prolymphocytic leukemia diagnosed from peripheral blood cell morphology.
  • These data indicated the common origin of the two coexisting leukemias and are the first example of such occurrence in a leukemic patient.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Prolymphocytic / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic
  • [MeSH-minor] Bone Marrow / pathology. Cell Lineage. Cytogenetic Analysis. Female. Gene Rearrangement. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860362.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Nakashima H, Saito B, Ariizumi H, Matsuda I, Nakamaki T, Tomoyasu S: [Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia]. Rinsho Ketsueki; 2008 Dec;49(12):1619-22
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia].
  • We report a case of B-cell prolymphocytic leukemia (B-PLL) that was treated successfully with splenic irradiation (SI).
  • Peripheral blood showed hemoglobin level 9.8 g/dl and white blood cell count 38.1x10(9)/l with 91% atypical cells.
  • A diagnosis of B-PLL was made.
  • [MeSH-major] Leukemia, Prolymphocytic, B-Cell / radiotherapy. Spleen

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110524.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Krishnan B, Matutes E, Dearden C: Prolymphocytic leukemias. Semin Oncol; 2006 Apr;33(2):257-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukemias.
  • T and B subtypes of prolymphocytic leukemias (PLLs) are rare, highly aggressive lymphoid malignancies with characteristic morphologic, immunophenotypical, cytogenetic, and molecular features.
  • Recent studies have highlighted the role of specific oncogenes such as TCL1, MTCP-1, and ATM in the case of T-cell and p53 mutations in the case of B-cell PLLs.
  • [MeSH-major] Leukemia, Prolymphocytic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616073.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


11. Crisostomo RH, Fernandez JA, Caceres W: Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia. Leuk Res; 2007 May;31(5):699-701
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia.
  • We report a case of a 64-year-old white female patient, who presented with symptomatic anemia (Hgb: 6.8g/dl), thrombocytopenia (platelets: 94,000/mcl) and leukocytosis (WBC: 156,000/mcl).
  • Peripheral blood smear revealed markedly increased white blood cell count with predominance of atypical lymphoid cells of intermediate size, moderately dense chromatin, and prominent large single nucleoli.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Leukemia, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997373.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Telek B, Batár P, Rejto L, Udvardy M: [Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol]. Orv Hetil; 2010 Aug 1;151(31):1261-3
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].
  • [Transliterated title] B-sejtes prolymphocytás leukaemia (B-PLL) sikeres kezelése FCR-Lite (fludarabin, cyclophosphamid, rituximab) protokoll alkalmazásával.
  • B-cell prolymphocytic leukemia (B-PLL) is a rare disorder characterized by marked lymphocytosis in the peripheral blood, matured lymphocytic infiltration in the bone marrow and splenomegaly.
  • The authors present a case of a patient with typical B-PLL treated with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol achieving complete hematological (and immunophenotypic) remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Prolymphocytic, B-Cell / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Humans. Immunophenotyping. Male. Prognosis. Rituximab. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20656663.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


13. Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D: IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia; 2006 Jul;20(7):1231-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
  • B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis.
  • To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases with de novo B-PLL.
  • [MeSH-major] Antigens, CD38 / genetics. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Membrane Glycoproteins / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642047.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Membrane Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


14. Inoue T, Yoshida M, Oowashi K, Yoshida T: [CD5-positive B-cell prolymphocytic leukemia]. Rinsho Ketsueki; 2010 Jan;51(1):80-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD5-positive B-cell prolymphocytic leukemia].
  • CD5 is a T-cell marker that is expressed in mature B cell malignancies and other B cell chronic lymphoproliferative disorders, but the biologic function of CD5 is unknown.
  • We report a 68-year-old woman with B-cell prolymphocytic leukemia (B-PLL) expressing CD5 antigen.
  • Hematological examination demonstrated a platelet count of 2.8 x 10(4)/microl and a white blood cell count of 19,900/microl with 69% PLL cells.
  • [MeSH-major] Antigens, CD5 / blood. Biomarkers, Tumor / blood. Leukemia, Prolymphocytic, B-Cell / blood. Leukemia, Prolymphocytic, B-Cell / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Female. Humans. Leukocyte Count. Platelet Count

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134145.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Dearden CE: T-cell prolymphocytic leukemia. Med Oncol; 2006;23(1):17-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive post-thymic malignancy with poor response to conventional treatment and short survival.
  • It can readily be distinguished from other T-cell leukemias on the basis of the distinctive morphology, immunophenotype, and cytogenetics.
  • Consistent chromosomal translocations involving the T-cell receptor gene and one of two protooncogenes (TCL-1 and MTCP-1) are seen in the majority of cases and are likely to be involved in the pathogenesis of the disorder.
  • However, relapse is inevitable and strategies using both autologous and allogeneic stem cell transplantation are currently being explored.
  • [MeSH-major] Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1996 Oct 1;10(19):2411-22 [8843194.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2331-4 [12613520.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Ann Hematol. 2001 Dec;80(12):749-51 [11797117.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Science. 1985 Mar 1;227(4690):1044-7 [3919442.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1923-7 [8634440.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1305-11 [9264385.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):248-54 [11391795.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5452-6 [9407948.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):336-41 [11241786.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2475-83 [8361760.001]
  • [Cites] Blood. 1998 May 15;91(10):3920-6 [9573030.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):921-7 [8703826.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] Lancet. 1973 Aug 4;2(7823):232-4 [4124423.001]
  • (PMID = 16645226.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


16. Foucar K: Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome. Am J Clin Pathol; 2007 Apr;127(4):496-510
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome.
  • The 2005 Society for Hematopathology/European Association for Haematopathology Workshop Session 1 was devoted to case presentations with discussions of 3 types of mature T-cell leukemias--T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome.
  • The application of clinical, morphologic, immunophenotypic, and genetic studies to the assessment and characterization of these 3 disorders is presented, along with specific diagnostic recommendations and differential diagnostic considerations.
  • [MeSH-major] Leukemia, Prolymphocytic / diagnosis. Leukemia, T-Cell / diagnosis. Sezary Syndrome / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD / metabolism. Chromosome Aberrations. Diagnosis, Differential. Humans. Immunophenotyping

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369126.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


17. Dungarwalla M, Matutes E, Dearden CE: Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol; 2008 Jun;80(6):469-76
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.
  • Prolymphocytic leukaemias of B and T cell subtype are rare diseases.
  • Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor.
  • Purine analogues and monoclonal antibodies have shown efficacy in B-cell prolymphocytic leukaemia although further studies are warranted.
  • Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T-cell prolymphocytic leukaemia (T-PLL) but responses are still transient and further disease progression is inevitable.
  • While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant.
  • [MeSH-major] B-Lymphocytes / immunology. Leukemia, Lymphoid / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Disease Progression. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331594.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 49
  •  go-up   go-down


18. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M: T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma; 2005 Nov;6(3):234-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: a single-institution experience.
  • BACKGROUND: T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes.
  • The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias.
  • PATIENTS AND METHODS: The clinical, pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D.
  • RESULTS: The most common cytogenetic abnormality was inv(14)(q11;q32), which was present in 7 patients.
  • In all 7 patients, this abnormality was associated with other chromosomal aberrations.
  • CONCLUSION: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Leukemia, Prolymphocytic / metabolism. Proto-Oncogene Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Chromosome Inversion. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354329.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human
  •  go-up   go-down


19. Absi A, Hsi E, Kalaycio M: Prolymphocytic leukemia. Curr Treat Options Oncol; 2005 May;6(3):197-208
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukemia.
  • Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features.
  • T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy.
  • We recommend alemtuzumab as initial therapy and offer stem cell transplant (SCT) to selected young, healthy patients who respond.
  • Although B-cell prolymphocytic leukemia is also a progressive disease, some patients can achieve a prolonged progression-free-survival with fludarabine.
  • Rituximab is a promising agent and further investigations are warranted to better define its role in treatment of this disorder.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, B-Cell / therapy. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / administration & dosage. Female. Humans. Male. Pentostatin / administration & dosage. Rituximab. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):169-79 [10194135.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):145-7 [14508807.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):230-1 [10706770.001]
  • [Cites] Eur J Haematol. 2001 Feb;66(2):137-9 [11168523.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Acta Haematol. 1999;102(2):94-8 [10529513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):571-81 [11293906.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3885-9 [9520462.001]
  • [Cites] Eur J Haematol. 1996 Apr;56(4):235-40 [8641392.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):220-7 [15072613.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Aug;55(1):1-9 [1913594.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):570-4 [7884417.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):37-43 [8996122.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Ann Hematol. 2004 May;83(5):319-21 [15060751.001]
  • [Cites] Am J Hematol. 1992 May;40(1):71-2 [1566752.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):391-4 [14663643.001]
  • [Cites] Semin Oncol. 1990 Oct;17(5 Suppl 8):66-70 [1699285.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3555-61 [14506141.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):46-50 [9020373.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):371-5 [8704689.001]
  • [Cites] Eur J Haematol. 1992 Jul;49(1):46-7 [1499697.001]
  • [Cites] Hematol Pathol. 1987;1(1):27-33 [3509770.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1305-11 [9264385.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1821 [1357112.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Anticancer Drugs. 2001 Jun;12 Suppl 2:S15-9 [11508932.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):981-7 [11697653.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6088-99 [7890742.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1284-5 [7738636.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):580 [8790162.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):175-88 [1702143.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):157-9 [8611452.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):149-51 [11908720.001]
  • [Cites] Jpn J Clin Oncol. 1998 Apr;28(4):267-9 [9657013.001]
  • [Cites] Ann Hematol. 1998 Feb;76(2):85-6 [9540763.001]
  • [Cites] Cancer Treat Res. 1993;64:105-19 [7680874.001]
  • [Cites] Clin Lymphoma. 2002 Sep;3(2):105-10 [12435283.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):114-20 [12491512.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • (PMID = 15869731.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 54
  •  go-up   go-down


20. Jahanmehr SA, Rogers M, Zheng J, Lai R, Wang C: Quantitation of cytological parameters of malignant lymphocytes using computerized image analysis. Int J Lab Hematol; 2008 Aug;30(4):278-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, image analysis program was used to quantitate cytological parameters of lymphocytes in B-cell lymphoproliferative disorders.
  • Chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and B-cell prolymphocytic leukemia (B-PLL) were selected to represent typically small, medium, and large-sized lymphocytes, respectively.
  • A set of measurements was generated for quantitation of total cell area, cell diameter, cytoplasm area, nuclear area, nuclear/cell ratio, and nuclear density.
  • The results from image analysis may assist in defining morphological criteria and in developing quantitative cell morphology.
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Prolymphocytic, B-Cell / pathology. Lymphoma, Mantle-Cell / pathology. Microscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665824.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Robak T, Robak P: Current treatment options in prolymphocytic leukemia. Med Sci Monit; 2007 Apr;13(4):RA69-80
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment options in prolymphocytic leukemia.
  • Prolymphocytic leukemia (PLL) is a rare lymphoproliferative disorder characterized by marked leukocytosis and splenomegaly.
  • PLL accounts for approximately 2% of chronic lymphoid leukemias.
  • The clinical course is progressive in the majority of cases due to the resistance of the disease to conventional chemotherapy.
  • The disease is divided according to the cell of origin into the B- (B-PLL) and T-cell (T-PLL) types.
  • Approximately 80% of cases are of B-cell phenotype.
  • PLL has poorer prognosis than chronic lymphocytic leukemia (CLL), and the patients with static disease for a longer period of time are rare.
  • PLL is still considered an incurable disease.
  • Finally, high-dose chemotherapy followed by allogenic or autologous stem cell transplantation seems to be an effective, probably curative, strategy for the treatment of selected patients with PLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia, Prolymphocytic / diagnosis. Leukemia, Prolymphocytic / drug therapy. Leukemia, Prolymphocytic / genetics. Purine Nucleosides / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / therapeutic use. Cladribine / therapeutic use. Drug Therapy / methods. Humans. Pentostatin / therapeutic use. Rituximab. Splenectomy / methods. Stem Cell Transplantation / methods. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392661.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Purine Nucleosides; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Number-of-references] 118
  •  go-up   go-down


22. Tarsitano M, Palmieri S, Ferrara F, Riccardi C, Cavaliere ML, Vicari L: Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia. Cancer Genet Cytogenet; 2009 Dec;195(2):164-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia.
  • The t(11;14)(q13;q32) is a hallmark of mantle cell lymphoma.
  • It has been found less frequently in other lymphoproliferative disorders, such as B-prolymphocytic leukemia, plasma cell leukemia, chronic lymphocytic leukemia, and multiple myeloma.
  • Here, we describe a patient with acute myeloid leukemia (AML), categorized as M5b according to French-American-British classification, in which conventional cytogenetic analysis revealed a karyotype with t(11;14)(q13;q32).
  • [MeSH-major] Cyclin D1 / genetics. Immunoglobulin Heavy Chains / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963117.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Immunoglobulin Heavy Chains; 136601-57-5 / Cyclin D1
  •  go-up   go-down


23. Madaris L: T-cell prolymphocytic leukemia: A rare disease in an elderly female. J Am Acad Nurse Pract; 2010 Dec;22(12):648-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: A rare disease in an elderly female.
  • This report includes a review of the morphology of T-cell prolymphocytic leukemia (PLL), diagnosis, and the treatment options considered.
  • DATA SOURCES: T-cell PLL is a rare blood disorder that represents a very small number of all chronic leukemias.
  • An extensive review of scientific literature related to the cell morphology and pathology of this disease, as well as clinical trials of treatment options provided the background for this case report.
  • CONCLUSION: A diagnosis of T-cell PLL was made after a computed tomography scan of the abdomen confirmed splenomegaly and a bone marrow biopsy showed a hypercellular marrow infiltrated with numerous small lymphocytes, consistent with this disease.
  • Currently, there is no optimal treatment for T-cell PLL, but alemtuzumab has shown success with extending survival 1-3 years.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia, Prolymphocytic, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 The Author Journal compilation ©2010 American Academy of Nurse Practitioners.
  • (PMID = 21129072.001).
  • [ISSN] 1745-7599
  • [Journal-full-title] Journal of the American Academy of Nurse Practitioners
  • [ISO-abbreviation] J Am Acad Nurse Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


24. Gandhi V, Tam C, O'Brien S, Jewell RC, Rodriguez CO Jr, Lerner S, Plunkett W, Keating MJ: Phase I trial of nelarabine in indolent leukemias. J Clin Oncol; 2008 Mar 1;26(7):1098-105
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of nelarabine in indolent leukemias.
  • PURPOSE: To test whether nelarabine is an effective agent for indolent leukemias and to evaluate whether there is a relationship between cellular pharmacokinetics of the analog triphosphate and clinical responses.
  • PATIENTS AND METHODS: Thirty-five patients with relapsed/refractory leukemias (n = 24, B-cell chronic lymphocytic leukemia and n = 11, T-cell prolymphocytic leukemia) were entered onto three different protocols.
  • Pharmacokinetics of plasma nelarabine and arabinosylguanine (ara-G) and of cellular ara-G triphosphate (ara-GTP) were similar in the two groups of diagnoses, and the elimination of ara-GTP from leukemia cells was slow (median, > 24 hours).
  • CONCLUSION: Nelarabine is an effective regimen against indolent leukemias, and combining it with fludarabine was most promising.
  • Determination of tumor cell ara-GTP levels may provide a predictive test for response to nelarabine.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Prolymphocytic, T-Cell / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18309944.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57629; United States / NCI NIH HHS / CA / CA81534
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Arabinonucleotides; 60158CV180 / nelarabine; 72490-81-4 / 9-beta-D-arabinofuranosylguanosine 5'-triphosphate; 86-01-1 / Guanosine Triphosphate; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


25. Zhang YN, Zhou XG, Zhang SH, Wang P, Zhang CH, Huang SF: [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2005 Apr;34(4):193-7
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms].
  • OBJECTIVE: To describe the relative frequency, morphologic features, immunophenotype and clinical data of different types of B-cell non-Hodgkin lymphoma (B-NHL) and to evaluate the practical application of the 2001 World Health Organization (WHO) classification of lymphoid neoplasms.
  • Diffuse large B-cell lymphoma, extranodal marginal zone lymphoma and follicular lymphoma were the commonest subtypes, accounting for 51.2% (189 cases), 14.9% (55 cases) and 10.6% (39 cases) of all cases respectively.
  • B-cell prolymphocytic leukemia and hairy cell leukemia were not identified.
  • When comparing the diagnosis based on morphologic examination alone with the diagnosis based on both morphology and immunophenotype, there was a 80% concordance rate.
  • Immunohistochemical study was helpful in reaching the correct diagnosis in many cases and could improve the overall diagnostic accuracy by about 20%.
  • CONCLUSIONS: Amongst cases of B-NHL, diffuse large B-cell lymphoma is the commonest subtype, followed by MALToma and follicular lymphoma.
  • While morphologic examination forms the basis for lymphoma diagnosis, immunohistochemical study also plays an important role in further subtyping.
  • A combination of both modalities are sufficient for arriving at an accurate diagnosis in most cases of B-NHL, in keeping with the recommendation of the 2001 WHO classification of lymphoid neoplasms.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / classification

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091170.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD43; 0 / Antigens, CD79
  •  go-up   go-down


26. Robak T: Emerging drugs for rarer chronic lymphoid leukemias. Expert Opin Emerg Drugs; 2008 Mar;13(1):95-118
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for rarer chronic lymphoid leukemias.
  • BACKGROUND: Rarer indolent lymphoid leukemias include well defined mature B-cell and T-cell neoplasm with widely varying natural history and specific morphological, immunophenotypic and molecular characteristics.
  • Among these are prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) and its variants, large granular lymphocyte leukemia (LGLL) and adult T-cell leukemia/lymphoma (ATLL).
  • OBJECTIVE: To present current therapies and emerging drugs potentially useful in the treatment of rarer chronic lymphoid leukemias.
  • Future research should focus on the novel therapeutic strategies based on the molecular pathogenic mechanisms and the development of new targeted therapies for each distinct chronic lymphoid leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drugs, Investigational / therapeutic use. Leukemia, Lymphoid / drug therapy
  • [MeSH-minor] Animals. Chronic Disease. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321151.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 189
  •  go-up   go-down


27. Robak T: Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr Med Chem; 2009;16(18):2212-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity.
  • Chronic lymphoid leukemias include well defined mature B-cell and T-cell neoplasms with diverse natural history and specific morphological, immunophenotypic and molecular characteristics.
  • The most common adult leukemia in the Western world is chronic lymphocytic leukemia (CLL).
  • Rarer indolent lymphoid leukemias include prolymphocytic leukemia, hairy cell leukemia, large granular lymphocyte leukemia and T-cell leukemia/lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Design. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519388.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 230
  •  go-up   go-down


28. Lundell R, Hartung L, Hill S, Perkins SL, Bahler DW: T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules. Am J Clin Pathol; 2005 Dec;124(6):937-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules.
  • T-cell large granular lymphocyte (T-LGL) leukemias represent monoclonal T-cell expansions that express CD16, CD56, or CD57 and cause cytopenias.
  • The identification of T-LGL leukemias can be difficult because reactive T-LGL cells also can express CD16, CD56, and CD57, and many leukemia cases show only mild lymphocytoses.
  • In this study, 23 T-LGL leukemia cases were analyzed by 3- and 4-color flow cytometry to identify markers that could aid in discriminating leukemic from normal T-LGL.
  • In most cases (18/23), abnormalities (bright, dim, or negative expression) of 2 or more pan-T-cell antigens were identified, with all cases showing abnormal CD5 levels.
  • These studies help define abnormal phenotypic features typical of T-LGL leukemia that may have important diagnostic value.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / metabolism. Biomarkers, Tumor / analysis. Histocompatibility Antigens Class I / metabolism. Leukemia, Prolymphocytic, T-Cell / diagnosis. Receptors, Antigen, T-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD5 / metabolism. Female. Flow Cytometry. Humans. Immunophenotyping. Killer Cells, Natural / metabolism. Male. Middle Aged. NK Cell Lectin-Like Receptor Subfamily D / metabolism. Receptors, Immunologic / metabolism. Receptors, KIR. Receptors, KIR2DL1. Receptors, KIR2DL2. Receptors, KIR2DL3. Receptors, KIR3DL1. Receptors, KIR3DL2. T-Lymphocytes / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416744.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class I; 0 / KIR2DL2 protein, human; 0 / NK Cell Lectin-Like Receptor Subfamily D; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR2DL1; 0 / Receptors, KIR2DL2; 0 / Receptors, KIR2DL3; 0 / Receptors, KIR3DL1; 0 / Receptors, KIR3DL2
  •  go-up   go-down


29. Usher SG, Radford AD, Villiers EJ, Blackwood L: RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Exp Hematol; 2009 Jan;37(1):65-77
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias.
  • OBJECTIVE: To determine the frequency of FLT3, C-KIT, and RAS mutations in canine leukemia patients.
  • MATERIALS AND METHODS: Ethylenediamine tetra-acetic acid blood samples were recruited from dogs with suspected leukemia, categorized by quantitative and cytological evaluation and immunophenotyping.
  • RESULTS: Fifty-seven (77.0%) of 74 samples submitted from dogs with suspected leukemia had cytologically and immunophenotypically confirmed leukemia.
  • There were 36 (63.2%) acute leukemias, 16 (28.1%) chronic, 3 (5.3%) prolymphocytic, 1 natural killer cell, and 1 chronic leukemia undergoing blast transformation.
  • N-RAS mis-sense mutations were identified in 14 (25%) dogs with acute myeloid (AML) or lymphoid (ALL) leukemia, and also in one dog in the leukemic phase of lymphoma.
  • Sixty-one percent of dogs with acute leukemia harbored mutations in N/K-RAS, FLT3, or C-KIT.
  • CONCLUSION: RAS, FLT3, and C-KIT mutations, analogous to those found in human leukemia, occur commonly in acute canine leukemia.
  • [MeSH-major] Dog Diseases / genetics. Leukemia / genetics. Leukemia / veterinary. Mutation. Proto-Oncogene Proteins c-kit / genetics. fms-Like Tyrosine Kinase 3 / genetics. ras Proteins / genetics
  • [MeSH-minor] Acute Disease. Animals. Antigens, CD / genetics. Antigens, CD / metabolism. Chronic Disease. Dogs

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18977066.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


30. Fidani L, Hatzitolios AI, Goulas A, Savopoulos C, Basayannis C, Kotsis A: Cholesteryl ester transfer protein TaqI B and lipoprotein lipase Ser447Ter gene polymorphisms are not associated with ischaemic stroke in Greek patients. Neurosci Lett; 2005 Aug 12-19;384(1-2):102-5
Hazardous Substances Data Bank. L-SERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholesteryl ester transfer protein (CETP) and lipoprotein lipase (LPL) are both key players in plasma lipoprotein homeostasis and, as such, genetically induced alterations in their respective activities may affect susceptibility to cerebrovascular diseases.
  • In this study, we examined the distribution of two common polymorphisms, namely CETP TaqI B and LPL Ser447Ter in a cohort of Greek clinically diagnosed late-onset ischaemic stroke patients (n = 98) and an ethnicity-, age- and sex-matched control group with no manifestations of vascular disease (n = 100).
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Cholesterol Ester Transfer Proteins. Female. Gene Frequency. Genetic Predisposition to Disease. Greece / epidemiology. Humans. Male. Odds Ratio

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896905.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CETP protein, human; 0 / Carrier Proteins; 0 / Cholesterol Ester Transfer Proteins; 0 / Glycoproteins; 452VLY9402 / Serine; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


31. Dixit M, Choudhuri G, Mittal B: Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study. Hepatol Res; 2006 Sep;36(1):61-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study.
  • INTRODUCTION: To identify high risk alleles for gallstone disease, we analyzed association of LDLRAvaII, LRPAP1 insertion/deletion, CETPTaqI B, and LPLHindIII polymorphisms with gallstone disease.
  • RESULTS: LRPAP1 gene insertion/deletion polymorphism was found to be significantly associated with gallstone disease.
  • Genotype II was conferring significant risk for gallstone disease in females only (P=0.019; OR 2.577, 95% CI 1.144-5.806).
  • LDLRAvaII, CETPTaqI B, and LPLHindIII polymorphisms were not found to be associated with gallstone disease either at genotype or allele level.
  • CONCLUSIONS: LRPAP1, II genotype carrier females may have increased risk for gallstone disease.
  • On the other hand, LDLR AvaII, CETP TaqI B, and LPL HindIII polymorphisms may not be associated with gallstone disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837242.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Malani AK, Gupta C, Rangineni R, Singh J, Ammar H: Concomitant presentation of acute myeloid leukemia with T-cell large granular lymphocytic leukemia. Acta Oncol; 2007;46(2):247-9
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant presentation of acute myeloid leukemia with T-cell large granular lymphocytic leukemia.
  • T-cell large granular lymphocyte leukemia (T-LGL) also known as T-cell chronic lymphocytic leukemia is rare and comprises a small minority of all small lymphocytic leukemias.
  • The concomitant presentation of T-LGL with acute myeloid leukemia (AML) has not been previously reported.
  • We present an elderly gentleman with concomitant T-LGL and AML (non-M3) diagnosed by a combination of morphologic evaluation, immunophenotyping by flow cytometry, and T-cell gene rearrangement studies.
  • He remains alive and well seven months after initial diagnosis.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Leukemia, Prolymphocytic, T-Cell / diagnosis
  • [MeSH-minor] Acute Disease. Aged, 80 and over. Antigens, CD / analysis. Flow Cytometry. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453377.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 17
  •  go-up   go-down


33. Belov L, Huang P, Chrisp JS, Mulligan SP, Christopherson RI: Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. J Immunol Methods; 2005 Oct 20;305(1):10-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells.
  • We have developed a microarray (DotScan) that enables rapid immunophenotyping and classification of leukaemias and lymphomas by measuring the capture of cells by immobilized dots of 82 CD antibodies [Belov, L., de la Vega, O., dos Remedios, C.G., Mulligan, S.P., 2001.
  • Immunophenotyping of leukemia using a cluster of differentiation antibody microarray. Cancer Res.
  • Identification of repertoires of surface antigens on leukemias using an antibody microarray.
  • After blocking the remaining nitrocellulose surface, individual arrays were incubated with each of 7 cell types from a human leukaemia cell panel consisting of three cell lines, CCRF-CEM (a T-cell acute lymphocytic leukaemia), MEC-1 (derived from B-cell chronic lymphocytic leukaemia) and HL-60 (a promyelocytic leukaemia), and four leukaemias from patients: a T-cell prolymphocytic leukaemia, a B-cell chronic lymphocytic leukaemia, and two acute myeloid leukaemias.
  • Leukaemia cells were captured by those immobilized antibodies for which they expressed the corresponding surface molecule.
  • The data obtained show the unique expression profiles of the 7 cell types in the leukaemia cell panel obtained with the DotScan microarray, and the differential capture patterns for these 7 cell types screened against the 498 antibodies in the HLDA8 microarray constructed for this study.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antigens, CD / analysis. Leukemia / classification. Protein Array Analysis / methods
  • [MeSH-minor] Cell Line, Tumor. Collodion / chemistry. Flow Cytometry. Humans. Leukemia, B-Cell / classification. Leukemia, B-Cell / immunology. Leukemia, Myeloid / classification. Leukemia, Myeloid / immunology. Leukemia, T-Cell / classification. Leukemia, T-Cell / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Nitrocellulose .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125720.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 9004-70-0 / Collodion
  •  go-up   go-down


34. Takizawa M, Matsushima T, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Murakami H, Nojima Y: [Unclassified mature T cell leukemia with cerebriform nuclei]. Rinsho Ketsueki; 2005 Jul;46(7):486-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unclassified mature T cell leukemia with cerebriform nuclei].
  • Adult T cell leukemia (ATL) and Sézary syndrome (SS) were ruled out because of the negative HTLV-1 test and the absence of skin lesions, respectively.
  • T-prolymphocytic leukemia (T-PLL), which is characterized by a marked increase in leukocytes having a CD7-phenotype and a progressive fatal course, was also excluded.
  • Recently, the TCL1 onco-protein has been shown to be overexpressed in progressive T-PLL but not in other mature T cell leukemias including Sézary syndrome.
  • In its morphology and phenotypes, our case resembled 'Sézary cell leukemia (SCL)' but the clinical course was much more indolent.
  • This case did not match any of the mature T cell leukemias defined in the WHO classification.
  • [MeSH-major] Cell Nucleus / ultrastructure. Leukemia, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440739.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human
  •  go-up   go-down


35. Troussard X, Cornet E: Outline for writing an article for current treatment options in oncology: splenic lymphoma with villous lymphocytes. Curr Treat Options Oncol; 2007 Apr;8(2):97-108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SLVL is a rare leukemic and indolent B-cell chronic lymphoproliferative disorder (B-CLPD) that we have to differentiate from hairy cell leukemia (HCL), B prolymphocytic leukemia (B-PLL) and follicular lymphoma (FL).
  • However, the diagnosis can be difficult to make on morphological criteria, especially in patients without absolute lymphocytosis.
  • SLVL has a relatively clinical benign course but a few patients could require treatment, because of a symptomatic splenomegaly and/or a severe cytopenia.
  • [MeSH-major] B-Lymphocytes / pathology. Lymphoma, B-Cell / therapy. Splenic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2002 Jun;3(1):41-7 [12141954.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1950-6 [10706860.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1558-62 [8123845.001]
  • [Cites] Lancet. 1992 Sep 5;340(8819):575-7 [1355156.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):759-64 [12614206.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):712-21 [9674745.001]
  • [Cites] Br J Haematol. 1998 Mar;100(3):609 [9504654.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4643-9 [16493005.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2050-7 [15389479.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):158-61 [9359516.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):513-7 [16049984.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):404-12 [12877667.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):392-8 [16480431.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1603-7 [7888678.001]
  • [Cites] Eur J Haematol. 2002 Aug;69(2):112-4 [12366716.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2727-37 [14630827.001]
  • [Cites] J Clin Pathol. 1992 Dec;45(12):1111-3 [1479039.001]
  • [Cites] J Clin Pathol. 1987 Jun;40(6):642-51 [3497180.001]
  • [Cites] Leuk Res. 1996 Nov-Dec;20(11-12):909-13 [9009248.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1212-3 [9886348.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):600-4 [10086800.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):731-6 [8652403.001]
  • [Cites] Haematologica. 2005 Apr;90(4):470-8 [15820942.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jan;36(1):57-69 [12461750.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1736-40 [9563492.001]
  • [Cites] Br J Haematol. 1993 Nov;85(3):487-91 [8136270.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jul 1;96(1):13-6 [9209463.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2659-61 [12239182.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):113-7 [11426611.001]
  • [Cites] Int J Hematol. 2005 Jun;81(5):413-6 [16158822.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1997 Mar-Apr;91(2):171-4 [9196759.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1648-54 [12176884.001]
  • [Cites] Blood Rev. 2005 Jan;19(1):39-51 [15572216.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):206-9 [2064958.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):134-40 [16405434.001]
  • [Cites] Leukemia. 2000 Apr;14(4):573-5 [10764141.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1924-5 [15385943.001]
  • [Cites] Eur J Haematol. 2005 Aug;75(2):130-5 [16000129.001]
  • (PMID = 17634839.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


36. Peggs KS, Mackinnon S, Linch DC: The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol; 2005 Jan;128(2):153-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although 40-60% of younger patients with diffuse large cell lymphoma can now expect to be cured, significant numbers will either fail to achieve a remission or relapse after attaining a remission.
  • In addition, certain histological subtypes are associated with particularly poor prognoses with combination chemotherapy alone (e.g. mantle cell lymphoma, B-cell prolymphocytic leukaemia).
  • Other NHL subtypes, whilst associated with more favourable prognoses in terms of overall survival, are rarely, if ever, cured (e.g. most low grade NHL including follicular lymphoma, chronic lymphocytic leukaemia and small lymphocytic lymphoma).
  • For these reasons dose escalation and allogeneic transplantation have been investigated as potential ways of improving outcome, although this has mainly been in the setting of advanced disease.
  • The parallel development of transplantation approaches that limit procedural toxicity along with advances in supportive care require that the role of allogeneic haematopoietic stem cell transplantation in the management of lymphoma be re-evaluated.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638849.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  •  go-up   go-down


37. Friedenson B: The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer; 2007;7:152
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study was designed to test the hypothesis that inactivation of virtually any component within the pathway containing the BRCA1 and BRCA2 proteins would increase the risks for lymphomas and leukemias.
  • These kinds of rearrangements are typically associated with some lymphomas and leukemias.
  • RESULTS: Deleterious mutations of genes encoding proteins virtually anywhere within the BRCA pathway increased risks up to nearly 2000 fold for certain leukemias and lymphomas.
  • Cancers with large increases in risk included mantle cell lymphoma, acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, and prolymphocytic leukemia.
  • Mantle cell lymphoma is defined by a characteristic rearrangement of DNA fragments interchanged between chromosomes 11 and 14.
  • CONCLUSION: An important function of the BRCA pathway is to prevent a subgroup of human leukemias and lymphomas that may involve non-random, characteristic gene rearrangements.
  • Inactivation of a single gene within the pathway can increase risks for multiple cancers and inactivation of a different gene in the same pathway may have similar effects.
  • [MeSH-minor] Adult. Child. Fanconi Anemia / genetics. Female. Genetic Predisposition to Disease. Humans. Leukemia / genetics. Lymphoma / genetics. Male. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4259-64 [11106241.001]
  • [Cites] J Clin Epidemiol. 2000 Nov;53(11):1119-29 [11106885.001]
  • [Cites] Am J Hum Genet. 2001 Mar;68(3):700-10 [11179017.001]
  • [Cites] EMBO J. 2003 Nov 3;22(21):5806-16 [14592978.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8717-25 [14695186.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3226-9 [15070707.001]
  • [Cites] Blood. 2004 Jul 15;104(2):350-5 [15059844.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):257-65 [15334549.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2007-15 [15370245.001]
  • [Cites] J Natl Cancer Inst. 1985 Aug;75(2):207-17 [3860679.001]
  • [Cites] Mol Cell. 1998 Feb;1(3):347-57 [9660919.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):175-82 [9739021.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] Leukemia. 1999 Mar;13(3):460-8 [10086737.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17108-13 [15563594.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1288-92 [15798766.001]
  • [Cites] Development. 2005 May;132(10):2263-72 [15829516.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):435-40 [11161413.001]
  • [Cites] Nat Immunol. 2000 Jul;1(1):77-82 [10881179.001]
  • [Cites] Nature. 2001 May 17;411(6835):336-41 [11357140.001]
  • [Cites] J Clin Pathol. 2001 Jul;54(7):512-6 [11429421.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38549-54 [11504724.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):758-9 [11745474.001]
  • [Cites] Blood. 2002 Jan 1;99(1):300-9 [11756185.001]
  • [Cites] Cell. 2002 Jan 25;108(2):171-82 [11832208.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):502-13 [12094236.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65 [12237281.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Nov;35(3):204-18 [12353263.001]
  • [Cites] Nat Cell Biol. 2002 Nov;4(11):865-70 [12402044.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4602-8 [12393693.001]
  • [Cites] Oncogene. 2002 Dec 16;21(58):8967-80 [12483513.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):425-40 [12518367.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1249-56 [12393516.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):289-94 [12692102.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1917-9 [12736286.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4247-56 [12773567.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4975-81 [12609845.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Science. 2003 Oct 24;302(5645):643-6 [14576434.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):813-22 [15928302.001]
  • [Cites] Nat Genet. 2005 Sep;37(9):931-3 [16116424.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6364-9 [16155021.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):255-65 [16153896.001]
  • [Cites] MedGenMed. 2005;7(2):60 [16369438.001]
  • [Cites] Mol Endocrinol. 2006 Jan;20(1):14-34 [16109739.001]
  • [Cites] Nucleic Acids Res. 2006;34(5):1416-26 [16522651.001]
  • [Cites] JAMA. 2006 Mar 22;295(12):1379-88 [16551709.001]
  • [Cites] Nature. 2006 Apr 20;440(7087):1045-9 [16625196.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:325-9 [4088306.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:99-112 [4088315.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Lancet. 1994 Mar 19;343(8899):692-5 [7907678.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4277-80 [8044771.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2358-64 [7662982.001]
  • [Cites] Blood. 1996 Jul 15;88(2):682-9 [8695816.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1144-50 [9067285.001]
  • [Cites] Am J Hum Genet. 1998 Feb;62(2):334-45 [9463314.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1338-43 [9537225.001]
  • [Cites] Hum Genet. 2006 Jun;119(5):479-95 [16572268.001]
  • [Cites] J Cell Sci. 2006 Jun 15;119(Pt 12):2518-31 [16735446.001]
  • [Cites] PLoS Med. 2006 Jun;3(6):e168 [16671833.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Oncogene. 2006 Sep 14;25(41):5693-706 [16636668.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):55-66 [17030982.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1108-13 [17047656.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):105-17 [17259967.001]
  • [Cites] Cell. 1999 Dec 10;99(6):577-87 [10612394.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):927-39 [10783165.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1400-6 [10837032.001]
  • [Cites] Leuk Res. 2000 Jul;24(7):553-8 [10867128.001]
  • [Cites] Cell. 2000 Jul 21;102(2):257-65 [10943845.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5548-52 [11034101.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):248-54 [11089982.001]
  • (PMID = 17683622.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein
  • [Number-of-references] 77
  • [Other-IDs] NLM/ PMC1959234
  •  go-up   go-down


38. Wang ZY, Chen QS: [Present status in studying immunotherapy for acute leukemia and its perspective--Editorial]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr;13(2):169-73
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Present status in studying immunotherapy for acute leukemia and its perspective--Editorial].
  • One of the important approaches for further prolonging remission duration and eradicating minimal residual disease in acute leukemia is immunotherapy.
  • Four kinds of immunotherapy for acute leukemia are under investigation:.
  • (1) monoclonal antibodies, among them, Mylotarg (cytotoxic antibiotic calicheamicin linked to CD33 Mab) is given for the treatment of refractory or relapsed acute myeloid leukemia and molecular relapse in acute promyelocytic leukemia with good results, Campath-1H (antiCD52 Mab) is administered in the treatment of prolymphocytic leukemia and Rituximab (anti-CD20 Mab) in B-PLL with high complete remission rates.
  • Other Mabs under preclinical and clinical trials include anti-IL-2 receptor Mab for the treatment of acute T lymphocytic leukemia, anti-220 kD Mab-6G7 for acute leukemias, recombinant immune toxin BL22 (anti-CD22) for hairy cell leukemia and Mabs labeled with radio-isotopes for different types of acute leukemias;.
  • (2) adoptive cellular immunotherapy using cytokine-induced killer cell, alloreactive NK cells, allogeneic or autologous leukemic-specific CD8(+) cytotoxic T lymphocytes, and other immune effector cells;.
  • (4) leukemia vaccines of several different formulations including antigen-specific, leukemia cell-based, leukemia antigen-pulsed dendritic cell (DC) and leukemia-derived DC vaccines, the latter two formulations are more attractive.
  • In conclusion, up to now, the most effective example of immunotherapy in acute leukemia is provided by the administration of Mabs, and the majority of other approaches in immunotherapy for acute leukemia although promising, need further studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854271.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines
  •  go-up   go-down


39. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, Brüggemann M, Bug S, Calasanz MJ, Deckert M, Dreyling M, Du MQ, Dürig J, Dyer MJ, Fan JB, Gesk S, Hansmann ML, Harder L, Hartmann S, Klapper W, Küppers R, Montesinos-Rongen M, Nagel I, Pott C, Richter J, Román-Gómez J, Seifert M, Stein H, Suela J, Trümper L, Vater I, Prosper F, Haferlach C, Cruz Cigudosa J, Siebert R: A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One; 2009 Sep 11;4(9):e6986
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas.
  • METHODOLOGY/PRINCIPAL FINDINGS: Here, we report for the first time a microarray-based DNA methylation study of 767 genes in 367 HNs diagnosed with 16 of the most representative B-cell (n = 203), T-cell (n = 30), and myeloid (n = 134) neoplasias, as well as 37 samples from different cell types of the hematopoietic system.
  • In general, promoter hypermethylation was more frequent in lymphoid malignancies than in myeloid malignancies, being germinal center mature B-cell lymphomas as well as B and T precursor lymphoid neoplasias those entities with highest frequency of gene-associated DNA hypermethylation.
  • We also observed a significant correlation between the number of hypermethylated and hypomethylated genes in several mature B-cell neoplasias, but not in precursor B- and T-cell leukemias.
  • Interestingly, T-cell prolymphocytic leukemias show low levels of DNA hypermethylation and a comparatively large number of hypomethylated genes, many of them showing an increased gene expression.
  • CONCLUSIONS/SIGNIFICANCE: We have characterized the DNA methylation profile of a wide range of different HNs entities.
  • As well as identifying genes showing aberrant DNA methylation in certain HN subtypes, we also detected six genes--DBC1, DIO3, FZD9, HS3ST2, MOS, and MYOD1--that were significantly hypermethylated in B-cell, T-cell, and myeloid malignancies.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2003 Sep 22;19(14):1832-6 [14512355.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):274-80 [12527896.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):3-11 [17489980.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2003;68:69-78 [15338605.001]
  • [Cites] Blood. 2001 May 1;97(9):2823-9 [11313277.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):808-14 [17299390.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1378-85 [17072317.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):39-45 [17970783.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4844-9 [18353987.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cytokine. 2009 Jan;45(1):8-11 [19071030.001]
  • [Cites] Cancer Lett. 2008 Nov 8;270(2):250-9 [18565646.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):697-704 [18288404.001]
  • [Cites] Blood. 2000 Aug 1;96(3):808-22 [10910891.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Pharmacogenet Genomics. 2009 Feb;19(2):95-102 [18987561.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):242-9 [15791568.001]
  • [Cites] Blood Rev. 2006 Jan;20(1):1-13 [16426940.001]
  • [Cites] Ann Hematol. 2005 Apr;84(4):236-44 [15538567.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3462-9 [17148581.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):285-90 [16126303.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2795-804 [19168792.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):137-44 [16846474.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4158-66 [12874021.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Curr Opin Oncol. 2008 Nov;20(6):705-10 [18841054.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1148-59 [18337604.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6118-28 [16778185.001]
  • [Cites] Ann Hematol. 2004 Mar;83(3):137-52 [15064862.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Sep;48(9):828-41 [19530241.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Eur J Immunol. 2004 Jul;34(7):1870-81 [15214035.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Leukemia. 2001 Apr;15(4):583-9 [11368360.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):758-64 [19155300.001]
  • [Cites] PLoS One. 2008;3(3):e1882 [18365023.001]
  • [Cites] Nat Genet. 2008 Feb;40(2):237-42 [18176563.001]
  • [Cites] J Clin Gastroenterol. 2009 Feb;43(2):152-6 [18779738.001]
  • [Cites] Bioinformation. 2007 Apr 10;1(10):420-2 [17597932.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8123-30 [16912190.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2153-63 [17713554.001]
  • [Cites] Cancer Invest. 2008 Dec;26(10):1037-43 [18798072.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] J Immunol. 2001 May 15;166(10):5925-34 [11342607.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Bioinformatics. 2003 Sep 22;19(14):1824-31 [14512354.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1315-25 [18832655.001]
  • [Cites] Nat Immunol. 2003 Feb;4(2):124-31 [12496962.001]
  • [Cites] Mod Pathol. 2008 May;21(5):632-8 [18264085.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2031-2 [19021042.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Aug;134(8):821-32 [18273643.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1855-62 [16900213.001]
  • [Cites] Leukemia. 2008 May;22(5):1035-43 [18288132.001]
  • [Cites] Oncogene. 2005 Oct 13;24(45):6848-54 [16007172.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14(8):997-1007 [15746151.001]
  • (PMID = 19750229.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2737286
  •  go-up   go-down


40. Maljaei SH, Asvadi-E-Kermani I, Eivazi-E-Ziaei J, Nikanfar A, Vaez J: Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders. Indian J Med Sci; 2005 May;59(5):187-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders.
  • BACKGROUND: Although many B-cell chronic lymphoproliferative disorders (BCLPDs) including B-cell chronic lymphocytic leukemia (B-CLL) have characteristic clinical and biological features, the overlapping morphologic and immunophenotypic profiles of various BCLPDs, is still the main problem.
  • MATERIALS AND METHODS: The expression of CD45 in 37 patients with BCLPD including typical B-CLL (Group I), atypical B-CLL and CLL/PLL (II), and hairy cell leukemia (HCL), B-prolymphocytic leukemia (B-PLL), and B-non Hodgkin's lymphoma (B-NHL) as non-CLL BCLPDs (III) and in eight healthy age matched controls (IV) was quantitatively compared by flow cytometric CD45/RALS gating strategy.
  • [MeSH-major] Antigens, CD45 / immunology. Leukemia, B-Cell / diagnosis. Membrane Proteins / biosynthesis. Phosphoproteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. Biomarkers / blood. Diagnosis, Differential. Female. Flow Cytometry. Fluorescent Antibody Technique, Direct. Follow-Up Studies. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985726.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / PTPRCAP protein, human; 0 / Phosphoproteins; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


41. Mikaelsson E, Danesh-Manesh AH, Lüppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA, Safaie R, Roohi A, Osterborg A, Shokri F, Mellstedt H, Rabbani H: Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood; 2005 Jun 15;105(12):4828-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
  • Fibromodulin is an extracellular matrix protein normally produced by collagen-rich tissues; the fibromodulin gene has been found to be the most overexpressed gene in B-cell chronic lymphocytic leukemia.
  • In this study, fibromodulin was expressed at the gene level (reverse transcription-polymerase chain reaction [RT-PCR]) in all patients with B-CLL (n = 75) and in most (5 of 7) patients with mantle cell lymphoma (MCL).
  • Fibromodulin was also detected at the protein level in the cytoplasm of the B-CLL cells and in the supernatant after in vitro cultivation, but not at the cell surface.
  • Fibromodulin was not found in patients with T-cell chronic lymphocytic leukemia (T-CLL), B-cell prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), hairy cell leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), or chronic myelogenous leukemia (CML) or in 36 hematologic cell lines.
  • [MeSH-major] Extracellular Matrix / metabolism. Extracellular Matrix Proteins / chemistry. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, Mantle-Cell / metabolism. Proteoglycans / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / biosynthesis. Antigens, CD19 / biosynthesis. Antigens, CD5 / biosynthesis. Antigens, Differentiation, T-Lymphocyte / biosynthesis. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Line, Transformed. Cell Line, Tumor. Coculture Techniques. Collagen / metabolism. Cytoplasm / metabolism. DNA Mutational Analysis. DNA, Complementary / metabolism. Female. Fibroblasts / metabolism. Flow Cytometry. Hematologic Neoplasms / metabolism. Humans. Immunoblotting. Lectins, C-Type. Leukemia, T-Cell / metabolism. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Mutation. Palatine Tonsil / metabolism. RNA, Messenger / metabolism. Receptors, Interleukin-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tetradecanoylphorbol Acetate / pharmacology. Time Factors

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741214.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD5; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / CD69 antigen; 0 / DNA, Complementary; 0 / Extracellular Matrix Proteins; 0 / Lectins, C-Type; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / Receptors, Interleukin-2; 126468-95-9 / fibromodulin; 9007-34-5 / Collagen; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


42. Ho AD, Hensel M: Pentostatin and purine analogs for indolent lymphoid malignancies. Future Oncol; 2006 Apr;2(2):169-83
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pentostatin has been shown to be active in a variety of B- and T-cell malignancies.
  • Early clinical trials indicated that this agent was highly active in acute lymphoblastic leukemias with high intracellular adenosine deaminase levels.
  • Through the efforts of a few investigators, better tolerated, low-dose regimens have been shown to be extremely active in lymphoproliferative diseases with very low intracellular adenosine deaminase levels such as hairy cell leukemia, B- and T-cell chronic leukemias, T-cell cutaneous lymphomas and low-grade non-Hodgkin lymphomas.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Leukemia, Hairy Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Prolymphocytic / drug therapy. Pentostatin / therapeutic use. Purine Nucleosides / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563086.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenosine Deaminase Inhibitors; 0 / Antibiotics, Antineoplastic; 0 / Purine Nucleosides; 395575MZO7 / Pentostatin
  • [Number-of-references] 92
  •  go-up   go-down


43. Del Giudice I, Osuji N, Dexter T, Brito-Babapulle V, Parry-Jones N, Chiaretti S, Messina M, Morgan G, Catovsky D, Matutes E: B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia; 2009 Nov;23(11):2160-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic, B-Cell / genetics


44. Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, Le Bris MJ, De Braekeleer M, Berthou C: A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Ann Hematol; 2009 Jan;88(1):85-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
  • [MeSH-major] Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols. Leukemia, Prolymphocytic, B-Cell / drug therapy. Mitoxantrone. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654781.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


45. Pamuk GE, Puyan FO, Unlü E, Oztürk E, Demir M: The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication. Leuk Res; 2009 Jun;33(6):864-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication.
  • [MeSH-major] Central Nervous System Diseases / complications. Leukemia, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929411.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


46. Chaar BT, Petruska PJ: Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol; 2007 May;82(5):417
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Prolymphocytic / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. B-Lymphocytes / pathology. Combined Modality Therapy. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Remission Induction. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160995.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


47. Castagna L, Sarina B, Todisco E, Mazza R, Santoro A: Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. Bone Marrow Transplant; 2005 Jun;35(12):1225
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation / adverse effects. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Autoimmune Diseases / etiology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Salvage Therapy. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880130.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down






Advertisement